By Professor Michelle Haber

Journal articles

Liu T, 2007, 'Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis', Proceedings of the National Academy of Sciences of the United States of America, 104, pp. 18682 - 18687, http://dx.doi.org/10.1073/pnas.0705524104

Cheng AJ; Cheng NC; Smith J; Murray JE; Flemming C; Marshall GM; Norris MD; Haber M, 2007, 'Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma', European Journal of Cancer, 43, pp. 1467 - 1475

Liu T; Kuljaca S; Haber M; Norris M; marshall G; Dwarte T; Tee ANDREW, 2007, 'Enhancing the anti-angiogenic action of histone deacetylase inhibitors', Molecular Cancer, 6, pp. 68 - 79, http://dx.doi.org/10.1186/1476-4598-6-68

Xue C; Haber M; Flemming C; Marshall GM; Lock RB; Mackenzie K; Norris MD; Gurova K; Gudkov A, 2007, 'p53 determines multidrug sensitivity of childhood neuroblastoma.', Cancer research, 67, pp. 10351 - 10360

Ashton LJ; Murray JE; Haber M; Marshall GM; Norris MD; Ashley DM, 2007, 'Polymorphisms in genes encoding drug metabolising enzymes and their influence on the outcome of children with neuroblastoma.', Pharmacogenetics and Genomics, 17, pp. 709 - 717

Choi S; Henderson M; Kwan EN; Sutton R; Giles J; Venn NC; Marshall GM; Haber M; Norris MD; Giles J, 2007, 'Relapse in children with acute lymphoblastic leukaemia involving selection of a pre-existing drug resistant subclone', Blood, 110, pp. 632 - 639

Munoz MA; Henderson M; Haber M; Norris MD, 2007, 'Role of the MRP1/ABCC1 multidrug transporter protein in cancer', IUBMB Life, 59, pp. 752 - 757

Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD, 2006, 'Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma', Journal of Clinical Oncology, 24, pp. 1546 - 1553

Cheung BB; Bell J; Raif A; Bohlken A; Yan J; Poljak A; Smith S; Lee M; Thomas WD; Kavallaris M; Norris MD; Haber M; Liu H; Zajchowski D; Marshall GM; bell , 2006, 'The estrogen-responsive B box protein is a novel regulator of the retinoid signal', The Journal of Biological Chemistry, 281, pp. 18246 - 18256

Laughton SJ; Ashton LJ; Kwan EN; Norris MD; Haber M; Marshall GM, 2005, 'Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in childhood acute lymphoblastic leukaemia', Journal of Clinical Oncology, 23, pp. 2264 - 2271

Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer G; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JA; Haber M, 2005, 'Expression of multi-drug transport MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro', Molecular Cancer Therapeutics, 4, pp. 547 - 553

Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer G; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JA; Haber M, 2005, 'Expression of multidrug ptransporter MRP4/ABCC4 is a marker of poor prognosis in nueroblastoma and confers resistance to irinotecan in vitro', Molecular Cancer Therapeutics, 4, pp. 547 - 553

Liu T; Bohlken A; Kuljaca S; Lee M; Nguyen T; Norris M; Haber M; marshall G; Smith S; Cheung B-B; Bowtell D, 2005, 'The retinoid anticancer signal: mechanisms of target gene regulation', British Journal of Cancer, 93, pp. 310 - 318, http://dx.doi.org/10.1038/sj.bjc.6602700

Pajic M; Norris MD; Cohn RJ; Haber M, 2005, 'The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome', Cancer Letters, 228, pp. 241 - 246

Liem N; Papa R; Milross CG; Schmid M; Tajbakhsh M; Choi S; Ramirez C; Rice AM; Haber M; Norris MD; Lock RB, 2004, 'Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies', Blood, 103, pp. 3905 - 3914, http://dx.doi.org/10.1182/blood-2003-08-2911

Hansford LM; Thomas WD; Keating JM; Burkhart C; Armati PJ; Weiss WA; Peaston AE; Norris MD; Haber M; Marshall GM, 2004, 'Mechanisms of embryonal tumor initination: Distinct roles for MycN expression and MYCN amlification.', Proceedings of the National Academy of Sciences of the United States of America, 101, pp. 12664 - 12669

Manohar CF; Bray JA; Salwen H; Madafiglio J; Cheng AJ; Flemming C; Marshall GM; Norris MD; Haber M; Cohn SL, 2004, 'MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma', Oncogene, 23, pp. 753 - 762

Don S; Verrills NM; Liaw T; Haber M; Norris MD; Kavallaris M, 2004, 'Neuronal-associated microtubule proteins class III B-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs.', Molecular Cancer Therapeutics, 3, pp. 1137 - 1146

Lastowska M; Chung Y; Ching Cheng C; Haber M; Norris MD; Kees UR; Pearson AA; Jackson M, 2004, 'Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.', Genes Chromosomes and Cancer, 40, pp. 158 - 163

Marshall G; Norris M; Haber M, 2003, 'Importance of minimal residual disease testing during the second year of disease: Still no answer? Reply', JOURNAL OF CLINICAL ONCOLOGY, 21, pp. 4464 - 4465, http://dx.doi.org/10.1200/JCO.2003.99.188

Hansford LM; Smith S; Haber M; Norris MD; Cheung BB; Marshall GM, 2003, 'Cloning and characterisation of the human neural cell adhesion molecule, (CNTN4) ( alias BIG-2)', Cytogenetic and Genome Research, 101, pp. 1 - 17

Nguyen TG; Hocker JE; Thomas WD; Smith SA; Norris MD; Haber M; Cheung BB; Marshall GM, 2003, 'Combined RAR and RXr-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells', Biochemical and Biophysical Research Communications, 302, pp. 462 - 468

Burkhart CA; Cheng AJ; Madafiglio J; Kavallaris M; Mili M; Marshall GM; Weiss WA; Khachigian LM; Norris MD; Haber M, 2003, 'Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma', Journal of National Cancer Institute, 95, pp. 1394 - 1403

Cheung BB; Yan JX; Smith SA; Nguyen TG; Lee M; Kavallaris M; Norris MD; Haber M; Marshall GM, 2003, 'Growth inhibitory retinoid effects after recruitment of retinoid X receptor B to the retinoic acid receptor B promoter', International Journal of Cancer, 105, pp. 856 - 867

Marshall GM; Haber M; Kwan EN; Zhu L; Ferrara D; Xue C; Brisco MJ; Sykes PJ; Morley A; Webster B; Dalla Pozza L; Waters K; Norris MD, 2003, 'Importance of minimal residual disease testing during teh second year of therapy for children with acute lymphoblastic leukemia', Journal of Clinical Oncology, 21, pp. 704 - 709

Verrills NM; Flemming C; Liu M; Ivery M; Cobon GS; Norris MD; Haber M; Kavallaris M, 2003, 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target', Chemistry and biology, 10, pp. 597 - 607

Pearson AJ; Haber M; Norris MD; Xue C; Flemming C; Lunec J; Tweddle D, 2003, 'The p53 pathway and its inactivitation in neuroblastoma', Cancer Letters, 197, pp. 93 - 98

Burkhart CA; Norris MD; Haber M, 2002, 'A simple method for the isolation of genomic DNA from mouse tail free of real-time PCR inhibitors', Journal of Biochemical and Biophysical Methods, 52, pp. 145 - 149

Efferth T; Verdorfer I; Miyachi H; Sauerbrey A; Drexler H; Chitambar C; Haber M; Gebhart E, 2002, 'Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines', Blood Cells Molecules and Diseases, 29, pp. 1 - 13

Gifford AJ; Haber M; Witt T; Whetstine JR; Taub JW; Matherly LH; Norris MD, 2002, 'Role of E45K reduced folate carrier gene mutation in methotrexate resistance in human leukaemia cells', Leukemia, 16, pp. 2379 - 2387

Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA; Lock RB; Maris JM; Merlino G; Patterson W; Reynolds CP; Shannon K; Yu A; Yu J; Smith MA, 2002, 'Testing of new agents in childhood cancer preclinical models(meeting summary)', Clinical Cancer Research, 8, pp. 3646 - 3657

Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM, 2002, 'The non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of Childhood acute lymphblastic leukemia reveals intrinsic differences in biological characteristics at diagnosis and relapse', Blood, 99, pp. 4100 - 4108

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Genomic and allelic expression status of the p73 gene in human neuroblastoma', Medical and Pediatric Oncology, 36, pp. 45 - 47, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<45::AID-MPO1012>3.0.CO;2-E

Norris MD; Madafiglio J; Gilbert J; Marshall GM; Haber M, 2001, 'Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study', Medical and Pediatric Oncology, 36, pp. 169 - 176, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours', Medical and Pediatric Oncology, 36, pp. 48 - 51, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<48::AID-MPO1013>3.0.CO;2-8

Kwan E; Lal A; Haber M; Norris MD; Marshall GM, 2001, 'Detection of minimal residual disease in peripheral blood prior to clonical relapse of childhood acute lympohoblastic leukaemia using PCR', Molecular and Cellular Probes, 15, pp. 99 - 103

Ekert H; Vivekanandan S; Chow CW; Marshall GM; Haber M; Norris MD, 2001, 'Expression of GAGE genes in neuroblastoma by reverse transcription - polymerase chain reaction', Cancer Research Therapy and Control, 11, pp. 197 - 203

Norris MD; Gilbert J; Smith A; Marshall GM; Salwen H; Cohn JN; Haber M, 2001, 'Expression of the Putative Tumour Suppressor Gene, p73, in Neuroblastome and Other Childhood Tumours', Medical Pediatric Oncology, pp. 48 - 51

Catts VS; Haber M; Norris MD; Lutze-Mann L; Lock RB, 2001, 'High Level resistance to Glucocorticoids, assosiated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, 15, pp. 929 - 935

Marshall GM; Norris MD; Lock RB; Peaston AE; Gardaneh M; Franco VA; Hocker JE; Murphy K; Farnsworth ML; Catchpoole DR; Haber M, 2001, 'MRP1 gene expression level regulates the death and differentation response of neuroblastoma cells', British Journal of Cancer, 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Kavallaris M; Tait AS; Norris MD; Haber M; Walsh B; He L; Horwitz SB, 2001, 'Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells', Cancer research, pp. 5803 - 5809

Norris MD; Marshall GM; Haber M; Gilbert J; Madafiglio J, 2001, 'Reversal of MRP-mediated drug resistance in cultured human neuroblastome cells by the quinlone antibiotic, difloxacin', Medical Pediatric Oncology, pp. 177 - 180

Norris MD; Madafiglio J; Gilbert J; Marshall GM; Haber M, 2001, 'Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin', MEDICAL AND PEDIATRIC ONCOLOGY, 36, pp. 177 - 180, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<177::AID-MPO1042>3.0.CO;2-Q

Whetstine JR; Gifford AJ; Witt T; Liu X; Flatley RM; Norris MD; Haber M; Taub JW; Ravindranath Y; Matherly LH, 2001, 'Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G.A variant at position 80 and transport properties of the his27 And Arg27 carriers', Clinical Cancer Research, 7, pp. 3416 - 3422, https://aacrjournals.org/clincancerres/article/7/11/3416/288667/Single-Nucleotide-Polymorphisms-in-the-Human

Norris MD; Burkhart CA; Marshall GM; Haber M, 2000, 'Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in murine neuroblastoma model', Medical and Pediatric Oncology, pp. 585 - 589

Cohn S; London WB; Huang K; Katzenstein HM; Salwen H; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M, 2000, 'MYCN expression is not prognostic of adverse outcomes in advanced-stage neuroblastoma with non-amplified MYCN', Journal of Clinical Oncology, 18, pp. 3604 - 3613

Kwan EN; Norris MD; Zhu L; Ferrara D; Marshall GM; Haber M, 2000, 'Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction', British Journal of Haematology, 109, pp. 430 - 434

Gardaneh M; Gilbert J; Haber M; Norris MD; Marshall GM, 2000, 'Synergy between 5` and 3` flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells', Neuroscience Letters, pp. 147 - 150

Marshall GM; Haber M; Kwan E; Zhou L; Ferrara D; Williams S; Brisco MJ; Morley A; Webster B; Dalla Pozza L; Tucker D; Waters K; Norris MD, 1999, 'The effect of late intensification of therapy in children with acute lymphoblastic leukaemia and minimal residual disease.', BLOOD, 94, pp. 658A - 658A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000083790302970&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn S; Salwen H; Schmidt ML; Norris MD; Gilbert J, 1999, 'Altered expression of the MYCN Oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells', Oncogene, 18, pp. 2777 - 2782

Back to profile page